Aberrant DNA methylation and prostate cancer

Current Genomics

Volumn 12, Issue 7, 2011, Pages 486-505

  Majumdar, Sunipa ^a   Buckles, Eric ^b   Estrada, John ^a   Koochekpour, Shahriar ^a,c  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DILLARD UNIVERSITY   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Epigenetics; Genome; Methylation; Prostate cancer

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANDROGEN RECEPTOR; AZACITIDINE; BISULFITE; DNA; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE INHIBITOR; EPIGALLOCATECHIN GALLATE; ESTROGEN RECEPTOR; GLUTATHIONE TRANSFERASE; HERMES ANTIGEN; HISTONE; HISTONE DEACETYLASE INHIBITOR; MATRIX METALLOPROTEINASE; MG 98; PROCAINAMIDE; PROCAINE; PROSTATE SPECIFIC ANTIGEN; RETINOIC ACID RECEPTOR; TRANSCRIPTION FACTOR; TRICHOSTATIN A; UVOMORULIN; VALPROIC ACID; VORINOSTAT; ZEBULARINE;

AMPLICON; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER INVASION; CELL CYCLE REGULATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CPG ISLAND; DENATURING GRADIENT GEL ELECTROPHORESIS; DNA DAMAGE; DNA METHYLATION; DNA MICROARRAY; DRUG MECHANISM; ENVIRONMENTAL FACTOR; EPIGENETICS; GENE EXPRESSION; GENE INTERACTION; GENETIC ASSOCIATION; GENOME IMPRINTING; HISTONE MODIFICATION; HUMAN; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METASTASIS; METHYLATION SENSITIVE RESTRICTION FINGERPRINTING; NONHUMAN; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN FUNCTION; RACE DIFFERENCE; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 80055118461     PISSN: 13892029     EISSN: 18755488     Source Type: Journal    
DOI: 10.2174/138920211797904061     Document Type: Article

References (230)

1. Jemal, A.; Center, M. M.; DeSantis, C.; Ward, E. M. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol. Biomarkers Prev., 2010, 19(8), 1893-1907.
2. Feinberg, A. P. The epigenetics of cancer etiology. Sem. Cancer Biol., 2004, 14, 427-432.
3. Schulz, W.A.; Hatina, J. Epigenetics of prostate cancer: beyond DNA methylation. J. Cell Mol. Med., 2006, 10, 100-125.
4. Rennie, P.S.; Nelson, C.C. Epigenetic mechanisms for progression of prostate cancer. Cancer Metastasis Rev., 1998-1999, 17, 401-409.
5. Li, L.C.; Carroll, P.R.; Dahiya, R. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J. Natl. Cancer Inst., 2005, 97, 103-115.
6. Ballestar, E. An introduction to epigenetics. Adv. Exp. Med. Biol., 2011, 711, 1-11.
7. Jones, P. A. An epigenetic approach for finding tumor suppressors, Cell Cycle, 2003, 2, 25-26.
8. Prendergast, G. C.; Ziff, E. B. Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region. Science, 1991, 251, 186-189.
9. Jones, P.L.; Veenstra, G.J.; Wade, P.A.; Vermaak, D.; Kass, S.U.; Landsberger, N.; Strouboulis, J.; Wolffe, A.P. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat. Genet., 1998, 19, 187-191.
10. Nan, X.; Ng, H.H.; Johnson, C.A.; Laherty, C.D.; Turner, B.M.; Eisenman, R.N.; Bird, A. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature, 1998, 393, 386-389.
11. Baylin, S. B. DNA methylation and gene silencing in cancer. Nat. Clin. Pract. Oncol., 2005, 2, S4-S11.
12. Bird, A. DNA methylation patterns and epigenetic memory. Genes Dev., 2002, 16, 6-21.
13. Bird, A. P. DNA methylation-how important in gene control? Nature, 1984, 307, 503-504.
14. Cross, S.H.; Bird, A.P. CpG islands and genes. Curr. Opin. Genet.Dev., 1995, 5, 309-14.
15. Okano, M.; Bell, D. W.; Haber, D. A.; Li, E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell, 1999, 99, 247-257.
16. Clarke, M. F. Epigenetic regulation of normal and cancer stem cells. Ann. N Y Acad. Sci., 2005, 1044, 90-93.
17. Laird, P. W. The power and the promise of DNA methylation markers. Nat. Rev. Cancer, 2003, 3, 253-266.
18. Weaver, J. R.; Susiarjo, M.; Bartolomei, M. S. Imprinting and epigenetic changes in the early embryo. Mamm. Genome, 2009, 20, 532-543.
19. Ogino, S.; Kawasaki, T.; Nosho, K.; Ohnishi, M.; Suemoto, Y.; Kirkner, G.J.; Fuchs, C.S. LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Int. J. Cancer, 2008, 122, 2767-2773.
20. Röhrs, S.; Dirks, W.G.; Meyer, C.; Marschalek, R.; Scherr, M.; Slany, R.; Wallace, A.; Drexler, H.G.; Quentmeier, H. Hypomethylation and expression of BEX2, IGSF4 and TIMP3 indicative of MLL translocations in Acute Myeloid Leukemia. Mol. Cancer, 2009, 8, 86.
21. Feinberg, A. P. Cancer epigenetics takes center stage. PNAS, 2001, 98, 392-394.
22. Ehrlich, M. DNA methylation and cancer-associated genetic instability. Adv. Exp. Med. Biol., 2005, 570, 363-392.
23. Niculescu, M.D.; Zeisel, S.H. Diet, methyl donors and DNA methylation: interactions between dietary folate, methionine and choline. J. Nutr. Suppl., 2002, 132, 23333S-23335S.
24. Li E, Bestor, T.H.; Jaenisch, R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell, 1992, 69, 915-926.
25. Doerfler W. Patterns of DNA methylation--evolutionary vestiges of foreign DNA inactivation as a host defense mechanism. A proposal. Biol. Chem. Hoppe. Seyler., 1991 372, 557-564.
26. Schulz, W.A. DNA methylation in urological malignancies. Int. J.Oncol., 1998, 13, 151-167
27. Gama-Sosa, M.A.; Slagel, V.A.; Trewyn, R.W.; Oxenhandler, R.; Kuo, K.C.; Gehrke, C.W.; Ehrlich, M. The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res., 1983, 11, 6883-6894.
28. Bedford, M.T.; van Helden, P.D. Hypomethylation of DNA in pathological conditions of the human prostate. Cancer Res., 1987, 47, 5274-5276.
29. Sakai, T.; Toguchida, J.; Ohtani, N.; Yandell, D.W.; Rapaport, J.M.; Dryja, T. P. Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am. J. Hum. Genet., 1991, 48, 880-888.
30. Herman, J.G.; Latif, F.; Weng, Y.; Lerman, M.I.; Zbar, B.; Liu, S.; Samid, D.; Duan, D.S.; Gnarra, J.R.; Linehan, W.M.; Baylin, S.B. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. PNAS, 1994, 91, 9700-9704.
31. Graff, J.R.; Herman, J.G.; Lapidus, R.G.; Chopra, H.; Xu, R.; Jarrard, D.F.; Isaacs, W.B.; Pitha, P.M.; Davidson, N.E.; Baylin, S.B. E-Cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res., 1995, 55, 5195-5199.
32. Reik, W.; Surani, M.A. Cancer genetics. Genomic imprinting and embryonal tumours. Nature, 1989, 338, 112-113.
33. Rainier, S.; Johnson, L.A.; Dobry, C.J.; Ping, A.J.; Grundy, P.E.; Feinberg, A.P. Relaxation of imprinted genes in human cancer. Nature, 1993, 362, 747-749.
34. Jarrard, D.F.; Bova, G.S.; Isaacs, W.B.DNA methylation, molecular genetics, and linkage studies in prostate cancer. Prostate, 1996, 6, 36-44.
35. Paul, R.; Ewing, C.M.; Jarrard, D.F.; Isaacs W.B. The Cadherin cell-cell adhesion pathway in prostate cancer progression. B r. J. Urol., 1997, 79, 37-43.
36. Jarrard, D.F.; Paul, R.; van Bokhoven, A.; Nguyen, S.H.; Bova, G.S.; Wheelock, M.J.; Johnson, K.R.; Schalken, J.; Bussemakers, M.; Isaacs, W.B. P-Cadherin is a basal cell-specific epithelial marker that is not expressed in prostate cancer. Clin. Cancer Res., 1997, 3, 2121-2128.
37. Li, L.C.; Zhao, H.; Shiina, H.; Kane, C.J.; Dahiya, R. PGDB: a curated and integrated database of genes related to the prostate. Nucleic Acids Res., 2003, 31, 291-293.
38. Gaudet, F.; Hodgson, J.G.; Eden, A.; Jackson-Grusby, L.; Dausman, J.; Gray, J.W.; Leonhardt, H.; Jaenisch, R. Induction of tumors in mice by genomic hypomethylation. Science, 2003, 300, 489-92.
39. Strange, R.C.; Spiteri, M.A.; Ramachandran, S.; Fryer, A.A. Glutathione-S-transferase family of enzymes. Mutat. Res., 2001, 482, 21-6.
40. Henderson, C.J.; McLaren, A.W.; Moffat, G.J.; Bacon, E.J.; Wolf, C.R. Pi-class glutathione S-transferase: regulation and function. Chem. Biol. Interact., 1998, 111-112, 69-82.
41. Brooks, J.D.; Weinstein, M.; Lin, X.; Sun, Y.; Pin, S.S.; Bova, G.S.; Epstein, J.I.; Isaacs, W.B.; Nelson, W.G. CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidemiol. Biomarkers Prev., 1998, 7, 531-536.
42. Nakayama, M.; Bennett, C.J.; Hicks, J.L.; Epstein, J.I.; Platz, E.A.; Nelson, W.G.; De Marzo, A.M. Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am. J. Pathol., 2003, 163, 923-933.
43. Esteller, M.; Herman, J.G. Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer. Oncogene, 2004, 23, 1-8.
44. Kang, G.H.; Lee, S.; Lee, H.J.; Hwang, K.S. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J. Pathol., 2004, 202, 233-240.
45. Konishi, N.; Nakamura, M.; Kishi, M.; Nishimine, M.; Ishida, E.; Shimada, K. DNA hypermethylation status of multiple genes in prostate adenocarcinomas. Jpn. J. Cancer Res., 2002, 93, 767-773.
46. Yamanaka, M.; Watanabe, M.; Yamada, Y.; Takagi, A.; Murata, T.; Takahashi, H.; Suzuki, H.; Ito, H.; Tsukino, H.; Katoh, T.; Sugimura, Y.; Shiraishi, T. Altered methylation of multiple genes in carcinogenesis of the prostate. Int. J. Cancer, 2003, 106, 382-387.
47. Maruyama, R.; Toyooka, S.; Toyooka, K.O.; Virmani, A.K.; Zochbauer-Muller, S.; Farinas, A.J.; Minna, J.D.; McConnell, J.; Frenkel, E.P.; Gazdar, A.F. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin. Cancer Res., 2002, 8, 514-519.
48. Heinlein, C.A.; Chang, C. Androgen receptor in prostate cancer. Endocr. Rev., 2004, 25, 276-308.
49. Gardiner-Garden, M.; Frommer, M. CpG islands in vertebrate genomes. J. Mol. Biol., 1987, 196, 261-282.
50. Jarrard, D.F.; Kinoshita, H.; Shi, Y.; Sandefur, C.; Hoff, D.; Meisner, L.F.; Chang, C.; Herman, J.G.; Isaacs, W.B.; Nassif, N. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res., 1998, 58, 5310-5314.
51. Newmark, J.R.; Hardy, D.O.; Tonb, D.C.; Carter, B.S.; Epstein, J.I.; Isaacs, W.B.; Brown, T.R.; Barrack, E.R. Androgen receptor gene mutations in human prostate cancer. Proc. Natl. Acad. Sci., 1992, 89, 6319-6323.
52. Visakorpi, T.; Hyytinen, E.; Koivisto, P.; Tanner, M.; Keinanen, R.; Palmberg, C.; Palotie A, Tammela T, Isola J, Kallioniemi O P. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet., 1995, 9, 401-406.
53. Gonzalgo, M.L.; Pavlovich, C.P.; Lee, S.M.; Nelson, W.G. Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. Clin. Cancer Res., 2003, 9, 2673-2677.
54. Kinoshita, H.; Shi, Y.; Sandefur, C; Meisner, L.F.; Chang, C; Choon, A.; Reznikoff, C.R.; Bova, G.S.; Friedl, A.; Jarrard, D.F. Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer. Cancer Res., 2000, 60, 3623-3630.
55. Nakayama, T.; Watanabe, M.; Suzuki, H.; Toyota, M.; Sekita N.; Hirokawa, Y; Mizokami, A.; Ito, H.; Yatani, R.; Shiraishi, T. Epigenetic regulation of androgen receptor gene expression in human prostate cancers. Lab. Invest., 2000, 80, 1789-1796.
56. Sasaki, M.; Tanaka, Y; Perinchery, G.; Dharia, A.; Kotcherguina, I.; Fujimoto, S.; Dahiya, R. Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer. J. Natl. Cancer Inst, 2002, 94, 384-90.
57. Huggins, C. Two principles in endocrine therapy of cancers: hormone deprival and hormone interference. Cancer Res., 1965, 25, 1163-1167.
58. Castagnetta, L.A.; Carruba, G. Human prostate cancer: a direct role for oestrogens. Ciba Found Symp., 1995, 191, 269-286.
59. Carruba, G.; Pfeffer, U.; Fecarotta, E.; Coviello, D.A.; D'Amato, E.; Lo Castro, M.; Vidali, G.; Castagnetta, L. Estradiol inhibits growth of hormone-nonresponsive PC3 human prostate cancer cells. Cancer Res., 1994, 54, 1190-1193.
60. Jarred, R.A.; McPherson, S.J.; Bianco, J.J.; Couse, J.F.; Korach, K.S.; Risbridger, G.P Prostate phenotypes in estrogen-modulated transgenic mice. Trends Endocrinol. Metab., 2002, 13, 163-168.
61. Leav, I.; Lau, K.M.; Adams, J.Y; McNeal, J.E.; Taplin, M.E.; Wang, J.; Singh, H.; Ho, S.M. Comparative studies of the estrogen receptors (3 and a and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am. J. Pathol, 2001, 159, 79-92.
62. Brolin, J.; Skoog, L.; Ekman, P. Immunohistochemistry and biochemistry in detection of androgen, progesterone, and estrogen receptors in benign and malignant human prostatic tissue. Prostate, 1992, 20, 281-295.
63. Hobisch, A.; Hittmair, A.; Daxenbichler, G.; Wille, S.; Radmayr, C; Hobisch-Hagen, P.; Bartsch, G.; Klocker, H.; Culig, Z. Metastatic lesions from prostate cancer do not express oestrogen and progesterone receptors. J. Pathol, 1997, 182, 356-361.
64. Horvath, L.G.; Henshall, S.M.; Lee, C.S.; Head, D.R.; Quinn, D.I.; Makela, S.; Delprado, W.; Golovsky, D.; Brenner, P.C.; O'Neill, G.; Kooner, R.; Stricker, P.D.; Grygiel, J.J.; Gustafsson, J.A.; Sutherland, R.L. Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Res., 2001, 61, 5331-5335.
65. Pasquali, D.; Rossi, V.; Esposito, D.; Abbondanza, C; Puca, G.A.; Bellastella, A.; Sinisi, A.A. Loss of estrogen receptor beta expression in malignant human prostate cells in primary cultures and in prostate cancer tissues. J. Clin. Endocrinol. Metab., 2001, 86, 2051-2055.
66. Li, L.C.; Chui, R.; Nakajima, K.; Oh, B.R.; Au, H.C.; Dahiya, R. Frequent methylation of estrogen receptor in prostate cancer: correlation with tumor progression. Cancer Res., 2000, 60, 702-706.
67. Li, L.C.; Yeh, C.C.; Nojima, D.; Dahiya, R. Cloning and characterization of human estrogen receptor beta promoter. Biochem. Biophys. Res. Commun., 2000, 275, 682-689.
68. Zhang, J.; Liu, L.; Pfeifer, G.P. Methylation of the retinoid response gene TIG1 in prostate cancer correlates with methylation of the retinoic acid receptor beta gene. Oncogene, 2004, 23, 2241-2249.
69. Nojima, D.; Li, L.C.; Dharia, A.; Perinchery, G.; Ribeiro-Filho, L.; Yen, T.S.; Dahiya, R. CpG hypermethylation of the promoter region inactivates the estrogen receptor-beta gene in patients with prostate carcinoma. Cancer, 2001, 92, 2076-2083.
70. Okuno, M.; Kojima, S.; Matsushima-Nishiwaki, R.; Tsurumi, H.; Muto, Y; Friedman, S.L.; Moriwaki, H. Retinoids in cancer chemoprevention. Curr. Cancer Drug Targets, 2004, 3, 285-298.
71. Van der Leede, B.J.; Folkers, G.E.; Kruyt, F.A.; Van der Saag, P.T. Genomic organization of the human retinoic acid receptor beta 2. Biochem. Biophys. Res. Commun., 1992, 188, 695-702.
72. Nakayama, T; Watanabe, M.; Yamanaka, M.; Hirokawa, Y; Suzuki, H.; Ito, H.; Yatani, R.; Shiraishi, T. The role of epigenetic modifications in retinoic acid receptor beta2 gene expression in human prostate cancers. Lab. Invest, 2001, 81, 1049-1057.
73. Woodson, K.; Gillespie, J.; Hanson, J.; Emmert-Buck, M.; Phillips, J.M.; Linehan, W.M.; Tangrea, J.A. Heterogeneous gene methylation patterns among pre-invasive and cancerous lesions of the prostate: a histopathologic study of whole mount prostate specimens. Prostate, 2004, 60, 25-31.
74. Woodson, K.; Hanson, J.; Tangrea, J. A survey of gene-specific methylation in human prostate cancer among black and white men. Cancer Lett., 2004, 205, 181-188.
75. Tokumaru, Y.; Harden, S.V.; Sun, D.I., Yamashita, K.; Epstein, J.I.; Sidransky, D. Optimal use of a panel of methylation markers with GSTP1 hypermethylation in the diagnosis of prostate adenocarcinoma. Clin. Cancer Res., 2004, 10, 5518-5522.
76. Singal, R.; Ferdinand, L.; Reis, I.M.; Schlesselman, J.J. Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease. Oncol. Rep., 2004, 12, 631-637.
77. Jerónimo, C.; Henrique, R.; Hoque, M.O.; Ribeiro, F.R.; Oliveira, J.; Fonseca, D.; Teixeira, M.R.; Lopes, C.; Sidransky, D. Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker. Clin Cancer Res., 2004, 10, 4010-4014.
78. Li, L.C.; Okino, S.T.; Dahiya, R. DNA methylation in prostate cancer. Biochim. Biophys. Acta., 2004, 1704, 87-102.
79. Jerónimo, C.; Henrique, R.; Hoque M.O.; Mambo, E.; Ribeiro, F.R.; Varzim, G.; Oliveira, J.; Teixeira, M.R.; Lopes, C.; Sidransky, D. A quantitative promoter methylation profile of prostate cancer. Clin. Cancer Res., 2004, 10, 8472-8478.
80. Nguyen, T.T.; Nguyen, C.T.; Gonzales, F.A.; Nichols, P.W.; Yu, M.C.; Jones, P.A. Analysis of cyclindependent kinase inhibitor expression and methylation patterns in human prostate cancers. Prostate, 2000, 43, 233-242.
81. Yegnasubramanian, S.; Kowalski, J.; Gonzalgo, M.L.; Zahurak, M.; Piantadosi, S.; Walsh, P.C.; Bova, G.S.; De Marzo, A.M.; Isaacs, W.B.; Nelson, W.G. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res., 2004, 64, 1975-1986.
82. Jarrard, D.F.; Bova, G.S.; Ewing, C.M.; Pin, S.S.; Nguyen, S.H.; Baylin, S.B.; Cairns, P.; Sidransky, D.; Herman, J.G.; Isaacs, W.B. Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. Genes Chromo. Cancer, 1997, 19, 90-96.
83. Gu, K.; Mes-Masson, A.M.; Gauthier, J.; Saad, F. Analysis of the p16 tumor suppressor gene in early-stage prostate cancer. Mol. Carcinog., 1998, 21, 164-170.
84. Hoque, M.O.; Topaloglu, O.; Begum, S.; Henrique, R.; Rosenbaum, E.; Van Criekinge, W.; Westra, W.H.; Sidransky, D. Quantitative methylation specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J. Clin. Oncol., 2005, 23, 6569-6575.
85. Florl, A.R.; Steinhoff, C.; Müller, M.; Seifert, H.H.; Hader, C.; Engers, R.; Ackermann, R.; Schulz, W.A. Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. B r. J. Cancer, 2004, 91, 985-994.
86. Herman, J.G.; Merlo, A.; Mao, L.; Lapidus, R.G.; Issa, J.P.; Davidson, N.E.; Sidransky, D.; Baylin, S.B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res., 1995, 55, 4525-4530.
87. Vos, M.D.; Ellis, C.A.; Bell, A.; Birrer, M.J.; Clark, G.J. Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J. Biol. Chem., 2000, 275, 35669-35672.
88. Dammann, R.; Li, C.; Yoon, J.H.; Chin, P.L.; Bates, S.; Pfeifer, G.P. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat. Genet., 2000, 25, 315-319.
89. Liu, L.; Yoon, J.H.; Dammann, R.; Pfeifer, G.P. Frequent hypermethylation of the RASSF1A gene in prostate cancer. Oncogene, 2002, 21, 6835-6840.
90. Greger, V.; Debus, N.; Lohmann, D.; Hopping, W.; Passarge, E.; Horsthemke, B. Frequency and parental origin of hypermethylated RB1 alleles in retinoblastoma. Hum. Genet., 1994, 94, 491-496.
91. Veigl, M.L.; Kasturi, L.; Olechnowicz, J.; Ma, A.H.; Lutterbaugh, J.D.; Periyasamy, S.; Li, G.M.; Drummond, J.; Modrich, P.L., Sedwick, W.D.; Markowitz, S.D. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc. Natl. Acad. Sci., 1998, 95, 8698-8702.
92. Li, L.C.; Zhao, H.; Nakajima, K.; Oh, B.R.; Ribeiro Filho, L.A.; Carroll, P.; Dahiya, R. Methylation of the E-Cadherin gene promoter correlates with progression of prostate cancer. Urology, 2001, 166, 705-709.
93. Watanabe, M.; Kakiuchi, H.; Kato, H.; Shiraishi, T.; Yatani, R.; Sugimura, T.; Nagao, M. APC gene mutations in human prostate cancer. Jpn. J. Clin. Oncol., 1996, 26, 77-81.
94. Gerstein, A.V.; Almeida, T.A.; Zhao, G.; Chess, E.; Shih, IeM.; Buhler, K.; Pienta, K.; Rubin, M.A.; Vessella, R.; Papadopoulos, N. APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers. Genes Chromosomes Cancer, 2002, 34, 9-16.
95. Bastian, P.J.; Ellinger, J.; Wellmann, A.; Wernert, N.; Heukamp, L.C.; Müller, S.C.; Von Ruecker, A. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin. Cancer Res., 2005, 11, 4097-4106.
96. Enokida, H.; Shiina, H.; Urakami, S.; Igawa, M.; Ogishima, T.; Li, L.C.; Kawahara, M.; Nakagawa, M.; Kane, C.J.; Carroll, P.R.; Dahiya, R. Multigene methylation analysis for detection and staging of prostate cancer. Clin. Cancer Res., 2005, 11, 6582-6588.
97. Shiina, H.; Breault, J.E.; Basset, W.W.; Enokida, H.; Urakami, S.; Li, L.C.; Okino, S.T.; Deguchi, M.; Kaneuchi, M.; Terashima, M.; Yoneda, T.; Shigeno, K.; Carroll, P.R.; Igawa, M.; Dahiya, R. Functional Loss of the gamma-catenin gene through epigenetic and genetic pathways in human prostate cancer. Cancer Res., 2005, 65, 2130-2138.
98. Sekita, N.; Suzuki, H.; Ichikawa, T.; Kito, H.; Akakura, K.; Igarashi, T.; Nakayama, T.; Watanabe, M.; Shiraishi, T.; Toyota, M.; Yoshie, O.; Ito, H. Epigenetic regulation of the KAI1 metastasis suppressor gene in human prostate cancer cell lines. Jpn. J. Cancer Res., 2001, 92, 947-951.
99. Schmitt, J.F.; Millar, D.S.; Pedersen, J.S.; Clark, S.L.; Venter, D.J.; Frydenberg, M.; Molloy, P.L.; Risbridger, G.P. Hypermethylation of the inhibin alpha-subunit gene in prostate carcinoma. Mol. Endocrinol., 2002, 16, 213-220.
100. Chen, H.; Toyooka, S.; Gazdar, A.F.; Hsieh, J.T. Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines. J. Biol. Chem., 2003, 278, 3121-3130.
101. Murphy, T.M.; Perry, A.S.; Lawler, M. The emergence of DNA methylation as a key modulator of aberrant cell death in prostate cancer. Endocr. Relat. Cancer, 2008, 15, 11-25.
102. Rouprêt, M.; Hupertan, V.; Yates, D.R.; Catto, J.W.; Rehman, I.; Meuth, M.; Ricci, S.; Lacave, R.; Cancel-Tassin, G.; de la Taille, A.; Rozet, F.; Cathelineau, X.; Vallancien, G.; Hamdy, F.C.; Cussenot, O. Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin. Cancer Res., 2007, 13, 1720-1725.
103. Park, J.; Brena, RM.; Gruidl, M.; Zhou, J.; Huang, T.; Plass, C.; Tockman, MS. CpG island hypermethylation profiling of lung cancer using restriction landmark genomic scanning (RLGS) analysis. Cancer Biomarkers, 2005, 1, 193-200.
104. Sørensen, K.D.; Wild, P.J.; Mortezavi, A.; Adolf, K.; Tørring, N.; Heebøll, S.; Ulhøi, BP.; Ottosen, P.; Sulser, T.; Hermanns, T.; Moch, H.; Borre, M.; Ørntoft, T.F.; Dyrskjøt, L. Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy. Clin. Cancer Res., 2009, 15, 1400-1410.
105. Shivapurkar, N.; Toyooka, S.; Toyooka, K.O.; Reddy, J.; Miyajima, K.; Suzuki, M.; Shigematsu, H.; Takahashi, T.; Parikh, G.; Pass, HI.; Chaudhary, P.M.; Gazdar, A.F. Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. Int. J. Cancer, 2004, 109, 786-792.
106. Van Noesel, M.M.; Va n Bezouw, S.; Salomons, G.S.; Voûte, P.A.; Pieters, R.; Baylin, S.B.; Herman, J.G.; Versteeg, R. Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation. Cancer Res., 2002, 62, 2157-2161.
107. Park, J.Y.; Zheng, W.; Kim, D.; Cheng, J.Q.; Kumar, N.; Ahmad, N.; Pow-Sang, J. Candidate tumor suppressor gene SLC5A8 is frequently down-regulated by promoter hypermethylation in prostate tumor. Cancer Detect. Prev., 2007, 31, 359-365.
108. Cho, N.Y.; Kim, B.H.; Choi, M.; Yoo, E.J.; Moon, K.C.; Cho, Y.M.; Kim, D.; Kang, G.H. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features. J. Pathol., 2007, 2 11, 269-277.
109. Cheng, Y.; Kim, J.W.; Liu, W.; Dunn, T.A.; Luo, J.; Loza, M.J.; Kim, S.T.; Zheng, S.L.; Xu, J.; Isaacs, W.B.; Chang, B.L. Genetic and epigenetic inactivation of TNFRSF10C in human prostate cancer. Prostate, 2009, 69, 327-335.
110. Hornstein, M.; Hoffmann, M.J.; Alexa, A.; Yamanaka, M.; Müller, M.; Jung, V.; Rahnenführer, J.; Schulz, WA. Protein phosphatase and TRAIL receptor genes as new candidate tumor genes on chromosome 8p in prostate cancer. Cancer Genomics Proteomics, 2008, 5, 123-136.
111. Stetler-Stevenson, W.G.; Aznavoorian, S.; Liotta, L.A. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu. Rev. Cell. Biol, 1993, 9, 541-573.
112. Takeichi, M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science, 1991, 251, 1451-1455.
113. Hirohashi, S.; Kanai, Y. Cell adhesion system and human cancer morphogenesis. Cancer Sci., 2003, 94, 575-581.
114. Quinn, D.I.; Henshall, S.M.; Sutherland, R.L. Molecular markers of prostate cancer outcome. Eur. J. Cancer, 2005, 41, 858-887.
115. Kallakury, B.V.; Sheehan, C.E.; Ross, J.S. Co-downregulation of cell adhesion proteins alpha-and beta-catenins, p120CTN, E-Cadherin, and CD44 in prostatic adenocarcinomas. Hum. Pathol, 2001, 32, 849-855.
116. Kallakury, B.V.; Sheehan, C.E.; Winn-Deen, E.; Oliver, J.; Fisher, H.A.; Kaufman, R. P.; Ross, J.A. Decreased expression of catenins (a and (3), p120 CTN, and E-Cadherin cell adhesion proteins and E-Cadherin gene promoter methylation in prostatic adenocarcinomas. Cancer, 2001, 92, 2786-2795.
117. Gokaslan, Z.L.; Chintala, S.K.; York, J.E.; Boyapati, V.; Jasti, S.; Sawaya, R.; Fuller, G.; Wildrick, D.M.; Nicolson, G.L.; Rao, J.S. Expression and role of matrix metalloproteinases MMP-2 and MMP-9 in human spinal column tumors. Clin. Exp. Metastasis, 1998, 16, 721-728.
118. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson, U.P Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur. J. Cell Biol, 1997, 74, 111-122.
119. Ross JS, Kaur P, Sheehan CE, Fisher, H.A.; Kaufman, R.A.; Kallakury, B.V. Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer. Mod. Pathol, 2003, 16, 198-205.
120. Gao, A.C.; Lou, W.; Dong, J.T.; Isaacs, J.T CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res., 1997, 57, 846-849.
121. Noordzij, M.A.; van Steenbrugge, G.J.; Verkaik, N.S.; Schröder, F.H.; van der Kwast, T.H. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy. Clin. Cancer Res., 1997, 3, 805-815.
122. Aaltomaa, S.; Lipponen, P.; Ala-Opas, M.; Kosma, V.M. Expression and prognostic value of CD44 standard and variant v3 and v6 isoforms in prostate cancer. Eur. Urol, 2001, 39, 138-144.
123. Harden, S.V.; Guo, Z.; Epstein, J.I.; Sidransky, D. Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma. J. Urol, 2003, 169, 1138-1142.
124. Lou, W.; Krill, D.; Dhir, R.; Becich, M.J.; Dong, J.T; Frierson, H.F.; Isaacs, W.B.; Isaacs, J.T; Gao, A.C. Methylation of the CD44 metastasis suppressor gene in human prostate cancer. Cancer Res., 1999, 59, 2329-2331.
125. Verkaik, N.S.; van Steenbrugge, G.J.; van Weerden, W.M.; Bussemakers, M.J.; van der Kwast, T.H. Silencing of CD44 expression in prostate cancer by hypermethylation of the CD44 promoter region. Lab. Invest., 2000, 80, 1291-1298.
126. Kito, H.; Suzuki, H.; Ichikawa, T; Sekita, N.; Kamiya, N.; Akakura, K.; Igarashi, T; Nakayama, T; Watanabe, M.; Harigaya, K.; Ito, H. Hypermethylation of the CD44 gene is associated with progression and metastasis of human prostate cancer. Prostate, 2001, 49, 110-115.
127. Woodson, K.; Hayes, R.; Wideroff, L.; Villaruz, L.; Tangrea, J. Hypermethylation of GSTP1, CD44, and E-Cadherin genes in prostate cancer among US Blacks and Whites. Prostate, 2003, 55, 199-205.
128. Padar, A.; Sathyanarayana, U.G.; Suzuki, M.; Maruyama, R.; Hsieh, J.T; Frenkel, E.P; Minna, J.D.; Gazdar, A.F. Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation. Clin. Cancer Res., 2003, 9, 4730-4734.
129. Bachmann, N.; Haeusler, J.; Luedeke, M.; Kuefer, R.; Perner, S.; Assum, G.; Paiss, T; Hoegel, J.; Vogel, W.; Maier, C. Expression changes of CAV1 and EZH2, located on 7q31 approximately q36, are rarely related to genomic alterations in primary prostate carcinoma. Cancer Genet. Cytogenet., 2008, 182,103-110.
130. Cui, J.; Rohr, L.R.; Swanson, G.; Speights, V.O.; Maxwell, T.; Brothman, A.R. Hypermethylation of the caveolin-1 gene promoter in prostate cancer. Prostate, 2001, 46, 249-256.
131. Alumkal, J.J.; Zhang, Z.; Humphreys, E.B.; Bennett, C.; Mangold, L.A.; Carducci, M.A.; Partin, A.W.; Garrett-Mayer, E.; DeMarzo, A.M.; Herman, J.G. Effect of DNA methylation on identification of aggressive prostate cancer. Urology, 2008, 72, 1234-1239.
132. Oudes, A.J.; Roach, J.C.; Walashek, L.S.; Eichner, L.J.; True, L.D.; Vessella, R.L.; Liu, A.Y. Application of Affymetrix array and Massively Parallel Signature Sequencing for identification of genes involved in prostate cancer progression. BMC Cancer, 2005, 5, 86.
133. Rehman, I.; Cross, S.S.; Catto, J.W.; Leiblich, A.; Mukherjee, A.; Azzouzi, A.R.; Leung, H.Y.; Hamdy, F.C. Promoter hyper-methylation of calcium binding proteins S100A6 and S100A2 in human prostate cancer. Prostate, 2005, 65, 322-330.
134. Guan, M.; Xu, C.; Zhang, F.; Ye, C. Aberrant methylation of EphA7 in human prostate cancer and its relation to clinicopathologic features. Int. J. Cancer, 2009, 124, 88-94.
135. Karam, J.A.; Lotan, Y.; Roehrborn, C.G.; Ashfaq, R.; Karakiewicz, P.I.; Shariat, S.F. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. Prostate, 2007, 67, 614-622.
136. Lee, S.W. H-Cadherin, a novel Cadherin with growth inhibitory functions and diminished expression in human breast cancer. Nat. Med., 1996, 2, 776-782.
137. Urnov, F.D. Methylation and the genome: the power of a small amendment. J. Nutr., 2002, 132, 2450S-2456S.
138. Dunn, B.K. Hypomethylation: one side of a larger picture. Ann. N.Y. Acad. Sci., 2003, 983, 28-42.
139. Santourlidis, S.; Florl, A.; Ackermann, R.; Wirtz, H.C.; Schulz, W.A. High frequency of alterations in DNA methylation in adenocarcinoma of the prostate. Prostate, 1999, 39, 166-174.
140. Schulz, W.A.; Elo, J.P.; Florl, A.R.; Pennanen, S.; Santourlidis, S.; Engers, R.; Buchardt, M.; Seifert, H.H.; Visakorpi, T. Genomewide DNA hypomethylation is associated with alterations on chromosome 8 in prostate carcinoma. Genes Chromosomes Cancer, 2002, 35, 58-65.
141. Brothman, A.R.; Swanson, G.; Maxwell, T.M.; Cui, J.; Murphy, K.J.; Herrick, J.; Speights, V.O.; Isaac, J.; Rohr, L.R. Global hypomethylation is common in prostate cancer cells: a quantitative predictor for clinical outcome? Cancer Genet. Cytogenet., 2005, 156, 31-36.
142. Ogishima, T.; Shiina, H.; Breault, J.E.; Tabatabai, L.; Bassett, W.W.; Enokida, H.; Li, L.C.; Kawakami, T.; Urakami, S.; Ribeiro-Filho, L.A.; Terashima, M.; Fujime, M.; Igawa, M.; Dahiya, R. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer. Clin. Cancer Res., 2005, 11, 1028-1036.
143. Tokizane, T.; Shiina, H.; Igawa, M.; Enokida, H.; Urakami, S.; Kawakami, T.; Ogishima, T.; Okino, S.T.; Li, L.C.; Tanaka, Y.; Nonomura, N.; Okuyama, A.; Dahiya, R. Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer. Clin. Cancer Res., 2005, 11, 5793-5801.
144. Sassaman, D.M.; Dombroski, B.A.; Moran, J.V.; Kimberland, M.L.; Naas, T.P.; DeBerardinis, R.J.; Gabriel, A.; Swergold, G.D.; Kazazian, H.H. Many human L1 elements are capable of retrotransposition. Nat. Genet., 1997, 16, 37-43.
145. Feinberg, A.P.; Vogelstein, B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature, 1983, 301, 89-92.
146. Feinberg, A.P.; Vogelstein, B. Hypomethylation of ras oncogenes in primary human cancers. Biochem. Biophys. Res. Commun., 1983, 111, 47-54.
147. Van Veldhuizen, P.J.; Sadasivan, R.; Cherian, R.; Wyatt, A. Urokinase-type plasminogen activator expression in human prostate carcinomas. Am. J. Med. Sci., 1996, 312, 8-11.
148. Helenius, M.A.; Saramaki, O.R.; Linja, M.J.; Tammela, T.L.; Visakorpi, T. Amplification of urokinase gene in prostate cancer. Cancer Res., 2001, 61, 5340-5344.
149. Pakneshan, P.; Xing, R.H.; Rabbani, S.A. Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo. FA S E B. J., 2003, 17, 1081-1088.
150. Cho, B.; Lim, Y.; Lee, D.Y; Park, S.Y; Lee, H.; Kim, W.H.; Yang, H.; Bang, Y.J.; Jeoung, D.I. Identification and characterization of a novel cancer/testis antigen gene CAGE. Biochem. Biophys. Res. Commun., 2002, 292, 715-726.
151. Cho, B.; Lee, H.; Jeong, S.; Bang, Y.J.; Lee, H.J.; Hwang, K.S.; Kim, H.Y; Lee, Y.S.; Kang, G.H.; Jeoung, D.I. Promoter hypomethylation of a novel cancer/testis antigen gene CAGE is correlated with its aberrant expression and is seen in premalignant stage of gastric carcinoma. Biochem. Biophys. Res. Commun., 2003, 307, 52-63.
152. Risch, N.; Merikangas, K. The future of genetic studies of complex human diseases. Science, 1996, 273(5281), 1516-1517.
153. Reams, R. R.; Agrawal, D.; Davis, M. B.; Yoder, S.; Odedina, F. T.; Kumar, N.; Higginbotham, J. M.; Akinremi, T.; Suther, S.; Soliman, K. F. Microarray comparison of prostate tumor gene expression in African-American and Caucasian American males: a pilot project study. Infect. Agent Cancer, 2009, 10, 4 Suppl 1: S3.
154. Kwabi-Addo, B.; Wang, S.; Chung, W.; Jelinek, J.; Patierno, S. R.; Wang, B. D.; Andrawis, R.; Lee, N. H.; Apprey, V.; Issa, J. P.; Ittmann, M. Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men. Clin. Cancer Res., 2010, 15(14), 3539-3547.
155. Woodson, K.; Hayes, R.; Wideroff, L.; Villaruz, L.; Tangrea, J. Hypermethylation of GSTP1, CD44, and E-Cadherin genes in prostate cancer among US Blacks and Whites. Prostate, 2003, 55(3), 199-205.
156. Kito, H.; Suzuki, H.; Ichikawa, T.; Sekita, N.; Kamiya, N.; Akakura K.; Igarashi T.; Nakayama, T.; Watanabe, M.; Harigaya, K.; Ito, H. Hypermethylation of the CD44 gene is associated with progression and metastasis of human prostate cancer. Prostate, 2001, 49(2), 110-115.
157. Li, B.; Carey, M.; Workman, J.L. The role of chromatin during transcription. Cell, 2007, 128, 707-719.
158. Klose, R.J.; Zhang, Y. Regulation of histone methylation by demethylimination and demethylation. Nat. Rev. Mol. Cell Biol., 2007, 8, 307-318.
159. Kouzarides, T. Chromatin modifications and their function. Cell, 2007, 128, 693-705.
160. Cedar, H.; Bergman, Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat. Rev. Genet., 2009, 10, 295-304.
161. Rando, O.J.; Chang, H.Y. Genome-wide views of chromatin structure. Annu. Rev. Biochem., 2009, 78, 245-271.
162. Kustatscher, G.; Ladurner, A.G. Modular paths to 'decoding' and 'wiping' histone lysine methylation. Curr. Opin. Chem. Biol, 2007, 11, 628-635.
163. McKinsey, T.A.; Zhang, C.L.; Olson, E.N. Control of muscle development by dueling HATs and HDACs. Curr. Opin. Genet. Dev, 2001, 11, 497-504.
164. Gray, S.G.; Ekstrom, T.J. The human histone deacetylase family. Exp. Cell Res., 2001, 262, 75-83.
165. Jones, PL.; Veenstra, G.J.; Wade, P.A.; Vermaak, D.; Kass, S.U.; Landsberger, N.; Strouboulis, J.; Wolffe, A.P. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat. Genet., 1998, 19, 187-191.
166. Goll, M.G.; Bestor, T.H. Histone modifi cation and replacement in chromatin activation. Genes Dev, 2002, 16, 1739-1742.
167. Jones, PA.; Baylin, S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet., 2002, 3, 415-428.
168. Fahrner, J.A.; Eguchi, S.; Herman, J.G.; Baylin, S.B. Dependence of histone modifi cations and gene expression on DNA hypermethylation in cancer. Cancer Res., 2002, 62, 7213-7218.
169. Nguyen, C.T.; Weisenberger, D.J.; Velicescu, M.; Gonzales, F.A.; Lin, J.C.; Liang, G.; Jones, P.A. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine. Cancer Res., 2002, 62, 6456-6461.
170. Dobosy, J.R.; Selker, E.U. Emerging connections between DNA methylation and histone acetylation. Cell Mol. Life Sci., 2001, 58, 721-727.
171. Halkidou, K.; Gnanapragasam, V.J.; Mehta, P.B.; Logan, I.R.; Brady, M.E.; Cook, S.; Leung, H.Y; Neal, D.E.; Robson, C.N. Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene, 2003, 22, 2466-2477.
172. Debes, J.D.; Schmidt, L.J.; Huang, H.; Tindall, D.J. p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res., 2002, 62, 5632-5636.
173. Yegnasubramanian, S.; Lin, X.; Haffner, M.C.; DeMarzo, A.M.; Nelson, W.G. Combination of methylated-DNA precipitation and methylation-sensitive restriction enzymes (COMPARE-MS) for the rapid, sensitive and quantitative detection of DNA methylation. Nucleic Acids Res., 2006, 34, e19.
174. Lee, W.H.; Isaacs, W.B.; Bova, G.S.; Nelson, W.G. CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: a new prostate cancer biomarker. Cancer Epidemiol. Biomarkers Prev., 1997, 6,443-450.
175. Clark, S.J.; Harrison, J.; Paul C.L.; Frommer M. High sensitivity mapping of methylated cytosines. Nucleic Acids Res., 1994, 22, 2990-2997.
176. Herman, J.G.; Graff, J.R.; Myöhänen, S.; Nelkin, B.D.; Baylin, S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci., 1996, 93, 9821-9826.
177. Miyamoto, K.; Ushijima, T. Diagnostic and therapeutic applications of epigenetics. Jpn. J. Clin. Oncol., 2005, 35, 293-301.
178. Lee, W.H.; Morton, R.A.; Epstein, J.I.; Brooks, J.D.; Campbell, P.A.; Bova, G.S.; Hsieh, W.S.; Isaacs, W.B.; Nelson, W.G. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl. Acad. Sci., 1994, 91, 11733-11737.
179. Harden, S.V.; Guo, Z.; Epstein, J.I.; Sidransky, D. Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma. J. Urol., 2003, 169, 1138-1142.
180. Jerónimo, C.; Usadel, H.; Henrique, R.; Silva, C.; Oliveira, J.; Lopes, C.; Sidransky, D. Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology, 2002, 60, 1131-1135.
181. Gonzalgo, M.L.; Nakayama, M.; Lee, S.M.; De Marzo, A.M.; Nelson, W.G. Detection of GSTP1 methylation in prostaticm secretions using combinatorial MSP analysis. Urology, 2004, 63, 414-418.
182. Goessl, C.; Muller, M.; Heicappell, R.; Krause, H.; Miller, K. DNA-based detection of prostate cancer in blood, urine, and ejaculates. Ann. N Y. Acad. Sci., 2001, 945, 51-58.
183. Bastian, P.J.; Ellinger, J.; Schmidt, D.; Wernert, N.; Wellmann, A.; Muller, S.C.; von Rücker, A. GSTP1 hypermethylation as a molecular marker in the diagnosis of prostatic cancer: is there a correlation with clinical stage, Gleason grade, PSA value or age? Eur. J. Med. Res., 2004, 9, 523-527.
184. Köllermann, J.; Müller, M.; Goessl, C.; Krause, H.; Helpap, B.; Pantel, K.; Miller, K. Methylation-specific PCR for DNAbased detection of occult tumor cells in lymph nodes of prostate cancer patients. Eur. Urol., 2003, 44, 533-538.
185. Das, P.M.; Singal, R. DNA methylation and cancer. J. Clin. Oncol., 2004, 22, 4632-4642.
186. Li, E. Chromatin modification and epigenetic reprogramming in mammalian development. Nat. Rev. Genet., 2002, 3,662-673.
187. Robert, M.F.; Morin, S.; Beaulieu, N.; Gauthier, F.; Chute, I.C.; Barsalou, A.; MacLeod, A.R.DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat. Genet., 2003, 33, 61-65.
188. Lin, X.; Tascilar, M.; Lee, W.H.; Vles, W.J.; Lee, B.H.; Veeraswamy, R.; Asgari, K.; Freije, D.; van Rees, B.; Gage, W.R.; Bova, G.S.; Isaacs, W.B.; Brooks, J.D.; DeWeese, T.L.; De Marzo, A.M.; Nelson, W.G. GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am. J. Pathol., 2001, 159, 1815-1826.
189. Taylor, S.M.; Jones, P.A. Changes in phenotypic expression in embryonic and adult cells treated with 5-azacytidine. J. Cell Phys., 1982, 111, 187-194.
190. Friedman, S. The irreversible binding of azacytosine containing DNA fragments to bacterial DNA (cytosine-5) methyltransferases. J. Biol. Chem., 1985, 260, 5698-5705.
191. Cheng, J.C.; Weisenberger, D.J.; Gonzales, F.A.; Liang, G.; Xu, G.L.; Hu, Y.G.; Marquez, V.E.; Jones, P.A. Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol. Cell Biol., 2004, 24, 1270-1278.
192. Lin, X.; Asgari, K.; Putzi, M.J.; Gage, W.R.; Yu, X.; Cornblatt, B.S.; Kumar, A.; Piantadosi, S.; DeWeese, T.L.; De Marzo, A.M.; Nelson, W.G. Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide. Cancer Res., 2001, 61, 8611-8616.
193. Villar-Garea, A.; Fraga, M.F.; Espada, J.; Esteller, M. Procaine is a DNAdemethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res., 2003, 63, 4984-4989.
194. Fang, M.Z.; Wang, Y.; Ai, N.; Hou, Z.; Sun, Y.; Lu, H.; Welsh, W.; Yang, C.S. Tea polyphenol epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res., 2003, 63, 7563-7570.
195. Bolden, J.E.; Peart, M.J.; Johnstone, R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov., 2006, 5, 769-784.
196. Chinnaiyan, P.; Vallabhaneni G.; Armstrong, E.; Huang, S.M.; Harari, P.M. Modulation of radiation response by histone deacetylase inhibition. Int. J. Radiat. Oncol. Biol. Phys., 2005, 62, 223-229.
197. Deroanne, C.F.; Bonjean, K.; Servotte, S.; Devy, L.; Colige, A.; Clausse, N.; Blacher, S.; Verdin, E.; Foidart, J.M.; Nusgens, B.V.; Castronovo, V. Histone deacetylases inhibitors as antiangiogenic agents altering vascular endothelial growth factor signaling. Oncogene, 2002, 21, 427-436.
198. Butler, L.M.; Agus, D.B.; Scher, H.I.; Higgins, B.; Rose, A.; Cordon-Cardo, C.; Thaler, H.T.; Rifkind, R.A.; Marks, P.A.; Richon, V.M. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res., 2000, 60, 5165-5170.
199. Marks, P.A.; Richon, V.M.; Miller, T.; Kelly, W.K. Histone deacetylase inhibitors. Adv. Cancer Res., 2004, 91, 137-168.
200. Qian, D.Z.; Kato, Y.; Shabbeer, S.; Wei, Y.; Verheul, H.M.; Salumbides, B.; Sanni, T.; Atadja, P.; Pili, R. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin. Cancer Res., 2006, 12, 634-642.
201. Burgess, A.; Ruefli, A.; Beamish, H.; Warrener, R.; Saunders, N.; Johnstone, R.; Gabrielli, B. Histone deacetylase inhibitors specifically kill non proliferating tumour cells. Oncogene, 2004, 23, 6693-6701.
202. Frommer, M.; McDonald, L. E.; Millar, D. S.; Collis, C. M.; Watt, F.; Grigg, G. W.; Molloy, P. L.; Paul, C. L. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl. Acad. Sci. USA, 1992, 89, 1827-1831.
203. Huang, T.H.; Laux, D.E.; Hamlin, B.C.; Tran, P.; Tran, H.; Lubahn, D. B. Identification of DNA methylation markers for human breast carcinomas using the methylation-sensitive restriction fingerprinting technique. Cancer Res., 1997, 57, 1030-1034.
204. Kuras, L. Characterization of protein-DNA association in vivo by chromatin immunoprecipitation. Methods Mol. Biol., 2004, 284, 147-162.
205. Karimi M.; Johansson, S.; Ekström, T. J. LUMA (LUminometric Methylation Assay)-A high throughput method to the analysis of genomic DNA methylation. Exp. Cell. Res., 2006, 312, 1989-1995.
206. Cedar, H.; Solage, A.; Glaser, G.; Razin, A. Direct detection of methylated cytosine in DNA by use of the restriction enzyme MspI. Nucleic Acids Res., 1979, 6, 2125-32.
207. Ronaghi, M. Pyrosequencing sheds light on DNA sequencing. Genome Res., 2001, 11, 3-11.
208. Tost, J.; El Abdalaoui, H.; Gut, I. G. Serial pyrosequencing for quantitative DNA methylation analysis. Biotechniques, 2006, 40, 721-722.
209. Shiao, Y.H.; Crawford, E. B.; Anderson, L.M.; Patel, P.; Ko K. Allele-specific germ cell epimutation in the spacer promoter of the 45S ribosomal RNA gene after Cr(III) exposure. Toxicol. Appl. Pharmacol., 2005, 205, 290-296.
210. Smith, L. M. The future of DNA sequencing. Science, 1993, 262, 530-532.
211. Hillenkamp, F.; Karas, M.; Beavis, R. C.; Chait, B. T. Matrix-assisted laser desorption/ionization mass spectrometry of biopolymers. Anal. Chem., 1991, 63, 1193A-1203A.
212. Fan, J.B.; Oliphant, A.; Shen, R.; Kermani, B.G.; Garcia, F.; Gunderson, K.L.; Hansen, M.; Steemers, F.; Butler, S.L.; Deloukas, P.; Galver, L.; Hunt, S.; McBride, C.; Bibikova, M.; Rubano, T.; Chen, J.; Wickham, E.; Doucet, D.; Chang, W.; Campbell, D.; Zhang, B.; Kruglyak, S.; Bentley, D.; Haas, J.; Rigault, P.; Zhou, L.; Stuelpnagel, J.; Chee, M.S. Highly parallel SNP genotyping. Cold Spring Harb. Symp. Quant. Biol., 2003, 68, 69-78.
213. Fan, J.B.; Gunderson, K.L.; Bibikova, M.; Yeakley, J.M.; Chen, J.; Wickham Garcia, E.; Lebruska, L.L.; Laurent, M.; Shen, R.; Barker, D. Illumina universal bead arrays. Methods Enzymol., 2006, 410, 57-73.
214. Aggerholm, A.; Holm, M.S.; Guldberg, P.; Olesen, L.H.; Hokland, P. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur. J. Haematol., 2006, 76, 23-32.
215. Cremonesi, L.; Firpo, S.; Ferrari, M.; Righetti, P.G.; Gelfi, C. Double-gradient DGGE for optimized detection of DNA point mutations. Biotechniques, 1997, 22, 326-330.
216. Reibenwein, J.; Pils, D.; Horak, P.; Tomicek, B.; Goldner, G.; Worel, N.; Elandt, K.; Krainer, M. Promoter hypermethylation of GSTP1, AR, and 14-3-3sigma in serum of prostate cancer patients and its clinical relevance. Prostate, 2007, 67, 427-432.
217. Jarrard, D. F.; Modder, J.; Fadden, P.; Fu, V, Sebree, L, Heisey, D.; Schwarze, S. R.; Friedl, A. Alterations in the p16/pRb cell cycle checkpoint occur commonly in primary and metastatic human prostate cancer. Cancer Lett., 2002, 185, 191-199.
218. Lodygin, D.; Epanchintsev, A.; Menssen, A.; Diebold, J.; Hermeking, H. Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res., 2005, 65, 4218-4227.
219. Pulukuri, S.M.; Patibandla, S.; Patel, J.' Estes, N.; Rao, J. S. Epigenetic inactivation of the tissue inhibitor of metalloproteinase-2 (TIMP-2) gene in human prostate tumors. Oncogene, 2007, 26, 5229-5237.
220. Pakneshan, P.; Szyf, M.; and Rabbani, S.A. Hypomethylation of urokinase (uPA) promoter in breast and prostate cancer: prognostic and therapeutic implications. Curr. Cancer Drug Targets, 2005, 5, 471-488.
221. Wakaguri, H.; Yamashita, R.; Suzuki, Y.; Sugano, S.; Nakai K. DBTSS: database of transcription start sites, progress report 2008. Nucleic Acids Res., 2008, 36(Database issue), D97-101.
222. Schmid, C. D.; Perier, R.; Praz, V.; Bucher, P. EPD in its twentieth year: towards complete promoter coverage of selected model organisms. Nucleic Acids Res., 2006, 34 (Database issue), D82-85.
223. Flicek, P.; Aken, B. L.; Ballester, B.; Beal, K.; Bragin, E.; Brent, S.; Chen, Y.; Clapham, P.; Coates, G.; Fairley, S.; Fitzgerald, S.; Fernandez-Banet, J.; Gordon, L.; Gräf, S.; Haider, S.; Hammond, M.; Howe, K.; Jenkinson, A.; Johnson, N.; Kähäri, A.; Keefe, D.; Keenan, S.; Kinsella, R.; Kokocinski, F.; Koscielny, G.; Kulesha, E.; Lawson, D.; Longden, I.; Massingham, T.; McLaren, W.; Megy, K.; Overduin, B.; Pritchard, B.; Rios, D.; Ruffier, M.; Schuster, M.; Slater, G.; Smedley, D.; Spudich, G.; Tang, Y. A.; Trevanion, S.; Vilella, A.; Vogel, J.; White, S.; Wilder, S. P.; Zadissa, A.; Birney, E.; Cunningham, F.; Dunham, I.; Durbin, R.; Fernández-Suarez, X. M.; Herrero, J.; Hubbard, T. J.; Parker, A.; Proctor, G.; Smith, J.; Searle, S. M. Ensembl's 10th year. Nucleic Acids Res., 2010, 38(Database issue):D557-D562.
224. Bock, C.; Reither, S.; Mikeska, T.; Paulsen, M.; Walter, J.; Lengauer, T. BiQ Analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing. Bioinformatics, 2005, 21(21), 4067-4068.
225. Li LC.; Dahiya, R. MethPrimer: designing primers for methylation PCRs. Bioinformatics, 2002, 18(11), 1427-31.
226. Rozen, S.; Skaletsky, H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol. Biol., 2000, 132, 365-386.
227. Eads, C. A.; Laird, P. W. Combined bisulfite restriction analysis (COBRA). Methods Mol. Biol., 2002, 200, 71-85.
228. Roberts, R. J.; Vincze, T.; Posfai, J.; Macelis, D.REBASE--a database for DNA restriction and modification: enzymes, genes and genomes. Nucleic Acids Res., 2010, 38(Database issue), D234-D236.
229. Grunau, C.; Renault, E.; Rosenthal, A.; Roizes, G. MethDB--a public database for DNA methylation data. Nucleic Acids Res., 2001, 29(1), 270-274.
230. Pattyn, F.; Hoebeeck, J.; Robbrecht, P.; Michels, E.; De Paepe, A.; Bottu, G.; Coornaert D.; Herzog, R.; Speleman, F.; Vandesompele, J. MethBLAST and methPrimerDB: web-tools for PCR based methylation analysis. BMC Bioinformatics, 2006, 7, 496.